GlaxoSmithKline (GSK) and iTeos Therapeutics are to co-develop and co-commercialise EOS-448, an anti-TIGIT monoclonal antibody currently in phase I development as a potential treatment for patients with cancer.
TIGIT, part of the CD226 checkpoint axis, has demonstrated potential as a promising target for the next generation of immuno-oncology therapies based on compelling preclinical data and a phase II randomised clinical trial.
With this collaboration GSK is uniquely positioned with access to antibodies that synergistically target all three known CD226 checkpoints – TIGIT, CD96 and PVRIG.
“Based on the underlying science, we believe that combinations of a PD-1, TIGIT, CD96 and PVRIG inhibitor could become transformative medicines for many patients with cancer. We are excited to collaborate with the team at iTeos and together we can play a leading role in the next generation of immuno-oncology therapies,” said Dr Hal Barron, Chief Scientific Officer and President R&D of GSK.
Under the terms of the collaboration agreement, iTeos will receive an upfront payment of $625 million.
iTeos will be eligible to receive up to an additional $1.45 billion in milestone payments, should the EOS-448 programme achieve certain development and commercial milestones.
Within the collaboration, GSK and iTeos will share responsibility and costs for the global development of EOS-448 and will jointly commercialise and equally split profits in the US.
Outside of the US, GSK will receive an exclusive license for commercialisation and iTeos will receive tiered royalty payments.